Home › Peptides A to Z › Angiotensin IIWhat is Angiotensin II? An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Angiotensin II in the library · · Human Trials · What are peptides?
38 registered trials · 1154 indexed papers · 1322 human / 413 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Type: Peptide hormone.
Definition (National Library of Medicine) “An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by angiotensin converting enzyme. The amino acid in position 5 varies in different species.”
Human research The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Angiotensin II is one of its interventions, or is named in the study title or subject headings.
Listing a study does not mean it showed a benefit, and it is not medical advice.
Registered human trials (38) Peer-reviewed studies (1154) Paper Authors Journal Year Type Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial Kalamar Ž et al. Critical care (London, England) 2026 Randomized Controlled Trial Angiotensin II regulates anxiety and social-affective top-down and bottom-up attention control in a sex-dependent manner Han M et al. Journal of affective disorders 2026 Randomized Controlled Trial Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study Yasar S et al. Journal of Alzheimer's disease : JAD 2026 Randomized Controlled Trial Acute GLP-1 infusion in male adults lowers circulating angiotensin II without changing angiotensinogen, ACE, ACE2, or angiotensin-(1-7) concentrations Asmar A et al. Physiological reports 2026 Randomized Controlled Trial Evaluating the Impact of a Standardized Protocol for Managing Refractory Vasoplegia After Cardiopulmonary Bypass Teletnick A et al. Journal of cardiothoracic and vascular anesthesia 2026 Observational Study Vasopressin and angiotensin II pathways differentially modulate human fear response dynamics to looming threats Han M et al. PLoS biology 2026 Randomized Controlled Trial Persistent renin-angiotensin system and inflammatory dysregulation following COVID-19 impairs ischemic stroke recovery Quek AML et al. Experimental and molecular pathology 2025 Observational Study Real-world Experience of Angiotensin II and Renin Usage in Patients With Distributive Shock:A Single-center Descriptive Study Möller Petrun A et al. Journal of cardiothoracic and vascular anesthesia 2025 Observational Study Increased Plasma Levels of ACE and Ang II in Prediabetes May Contribute to Adipose Tissue Dysfunction Mkhize BC et al. International journal of molecular sciences 2025 Observational Study Increased formation of angiotensin II from angiotensin I in individuals of African descent Gandhi SK et al. Journal of hypertension 2025 Randomized Controlled Trial Serum C-Terminal Agrin Fragment With Acute and Long-Term Exercise and Angiotensin II Type I Receptor Blockade Soendenbroe C et al. Journal of cachexia, sarcopenia and muscle 2025 Randomized Controlled Trial A Prospective double-blind, randomised controlled trial comparing angiotensin II to norepinephrine to reduce length of hospital stay in cardiac surgery patients (the PORTHOS study protocol) Coulson TG et al. BMJ open 2025 Clinical Study Subclinical Primary Aldosteronism Is Characterized by Maladaptive Natriuretic Peptide and Adrenal Hormonal Physiology Parisien-La Salle S et al. The Journal of clinical endocrinology and metabolism 2025 Observational Study Evaluation of Angiotensin II in Patients With Catecholamine-Resistant Vasodilatory Shock Requiring Continuous Renal Replacement Therapy (ANGEL CRRT) Rettele MA et al. Journal of cardiothoracic and vascular anesthesia 2025 Observational Study An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock Leisman DE et al. Critical care (London, England) 2025 Randomized Controlled Trial A Pilot, Single-Blinded, Randomized Crossover Trial of Cramp Reduction with Angiotensin II in Maintenance Patients on Hemodialysis (the CRAMP-HD Study) Phongphithakchai A et al. American journal of nephrology 2025 Randomized Controlled Trial ANGIOTENSIN II FOR CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY: A POST HOC ANALYSIS OF THE ATHOS-3 TRIAL Chaba A et al. Shock (Augusta, Ga.) 2025 Randomized Controlled Trial The Effects of Angiotensin II versus Norepinephrine on Pulmonary Vascular Resistance in Cardiac Surgery: Post Hoc Analysis of a Randomized Controlled Trial Lim J et al. Journal of cardiothoracic and vascular anesthesia 2024 Randomized Controlled Trial Monoamine Oxidase Contributes to Valvular Oxidative Stress: A Prospective Observational Pilot Study in Patients with Severe Mitral Regurgitation Șoșdean R et al. International journal of molecular sciences 2024 Observational Study Intra- and postoperative relative angiotensin II deficiency in patients undergoing elective major abdominal surgery Krenn K et al. Frontiers in endocrinology 2024 Observational Study Angiotensin II treatment of hypotension in noncardiac surgery: an initial dose-finding study Fernando RJ et al. British journal of anaesthesia 2024 Randomized Controlled Trial Vitamin D3 supplementation in COVID-19 patients with cardiovascular disease and gut dysbiosis Sanz RL et al. Hipertension y riesgo vascular 2024 Randomized Controlled Trial The REPERFUSE study protocol: The effects of vasopressor therapy on renal perfusion in patients with septic shock-A mechanistically focused randomised control trial McDonald R et al. PloS one 2024 Clinical Study ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock Leisman DE et al. Critical care (London, England) 2024 Randomized Controlled Trial Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent Hypotension See EJ et al. Critical care medicine 2024 Observational Study The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock Teixeira JP et al. Trials 2024 Clinical Study Study on the mechanism underlying Trichosanthis peel injection-induced improvements in myocardial fibrosis markers in patients with chronic heart failure He Y et al. Clinical and experimental pharmacology & physiology 2024 Randomized Controlled Trial A Pilot Study of Renin-Guided Angiotensin-II Infusion to Reduce Kidney Stress After Cardiac Surgery Sadjadi M et al. Anesthesia and analgesia 2024 Randomized Controlled Trial A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol Anggraini YE et al. Trials 2024 Clinical Study Maternal plasma angiotensin 1-7 concentration is related to twin pregnancy chorionicity in the third trimester of pregnancy Pietruski P et al. Frontiers in endocrinology 2023 Observational Study
More cited research Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression (2002, human observational)Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta (1997, human observational)Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart (1990, human observational)The ovarian renin-angiotensin system: renin-like activity and angiotensin II/III immunoreactivity in gonadotropin-stimulated and unstimulated human follicular f (1987, human observational)Sirt6 deficiency exacerbates angiotensin II-induced lipid nephrotoxicity by affecting PLD6-derived cardiolipin metabolism in podocytes (2025, animal)Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: compari (2025, animal)Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II-induced hypertension (2021, animal)Nicotinamide riboside rescues angiotensin II-induced cerebral small vessel disease in mice (2020, animal)Conditions researched Anemia Anti-aging & longevity Anxiety and panic Atherosclerosis, cardiovascular disease & high blood pressure Chronic and systemic inflammation Cognition, focus & brain performance Concussion, traumatic brain injury & stroke recovery Dementia, Alzheimer's & cognitive decline Fat loss, obesity & body recomposition Fatty liver & elevated liver enzymes Gout Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers Heart repair: after heart attack, heart failure & enlarged heart High cholesterol and statins High-demand jobs: military, fire, police, EMT (and combat-sport athletes) Immune system (general) Insulin resistance, prediabetes & type 2 diabetes Kidney protection (CKD, diabetic kidney, lupus kidney) Low blood pressure and orthostatic hypotension Lung health, asthma & COPD Migraine Muscle gain, sarcopenia & building muscle after 40 PCOS Post-surgical inflammation and surgery recovery POTS and dysautonomia Pregnancy and breastfeeding: safety notes Psoriasis and psoriatic arthritis Raynaud's Skin, hair loss, wounds & mast-cell/histamine reactivity Sleep apnea (obstructive) Sleep problems (incl. insomnia on peptides) Thick blood and blood clots Related compounds FAQ What is Angiotensin II? An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
How many registered human trials study Angiotensin II? The PeptideWhiz trial index lists 38 registered trials for Angiotensin II, the most recent from 2026.
How much published research exists on Angiotensin II? The PeptideWhiz paper index links 1154 PubMed papers to Angiotensin II; by study type, 1322 human and 413 animal studies.
Which conditions is Angiotensin II researched for? Anemia, Anti-aging & longevity, Anxiety and panic, Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery, Dementia, Alzheimer's & cognitive decline, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Gout, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Heart repair: after heart attack, heart failure & enlarged heart, High cholesterol and statins, High-demand jobs: military, fire, police, EMT (and combat-sport athletes), Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low blood pressure and orthostatic hypotension, Lung health, asthma & COPD, Migraine, Muscle gain, sarcopenia & building muscle after 40, PCOS, Post-surgical inflammation and surgery recovery, POTS and dysautonomia, Pregnancy and breastfeeding: safety notes, Psoriasis and psoriatic arthritis, Raynaud's, Skin, hair loss, wounds & mast-cell/histamine reactivity, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides), Thick blood and blood clots.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).
Reported dosing ranges from research